- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00153608
WT1 Peptid Vaccination in Carcinomas
February 13, 2006 updated by: Charite University, Berlin, Germany
Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Carcinomas
In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
25
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carmen Scheibenbogen, MD
- Phone Number: +49-30-8445-4576
- Email: carmen.scheibenbogen@charite.de
Study Locations
-
-
-
Berlin, Germany, 12200
- Recruiting
- Hem&Onc Charité CBF
-
Contact:
- Carmen Scheibenbogen, MD
- Phone Number: +49-30-8445-4576
- Email: carmen.scheibenbogen@charite.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Metastatic cancer, no standard treatment option
- Resected cancer with minimal residual disease, no standard treatment option
- WT-1 expression
- HLA-A2
Exclusion Criteria:
- Concurrent chemotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Clinical efficacy
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety
|
Immune response
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ulrich Keilholz, MD, Charité CBF
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2004
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
February 14, 2006
Last Update Submitted That Met QC Criteria
February 13, 2006
Last Verified
September 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HaemaCBFWT104
- EU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on WT1 Expressing Carcinoma
-
RemeGen Co., Ltd.RecruitingUrothelial Carcinoma | HER2-expressingChina
-
Hassane M. Zarour, MDNational Cancer Institute (NCI)Completed
-
Ichnos Sciences SAGlenmark Pharmaceuticals S.A.TerminatedHER2 Expressing Solid TumoursUnited States, Germany
-
Jazz PharmaceuticalsALX Oncology Inc.RecruitingHER2-expressing CancersUnited States
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingHER2-expressing Advanced Solid TumorsChina
-
Merck Sharp & Dohme LLCCompletedCancers Expressing HER-2 and/or CEA
-
BayerCompletedAdvanced CEACAM6-expressing Solid TumorsUnited States, Singapore, Canada
-
Advaxis, Inc.CompletedHER2 Expressing Solid TumorsUnited States
-
Amunix, a Sanofi CompanyMerck Sharp & Dohme LLCRecruitingLocally Advanced or Metastatic HER2-Expressing CancersAustralia, Spain, France, Portugal
-
GeneQuantum Healthcare (Suzhou) Co., Ltd.RecruitingHER2 Expressing or Mutated Advanced Malignant Solid TumorsChina
Clinical Trials on WT1 126-134 peptide
-
Charite University, Berlin, GermanyUnknownAcute Myeloid Leukemia | Myelodysplastic SyndromeGermany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedAcute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)United States
-
University Hospital Southampton NHS Foundation...Imperial College Healthcare NHS Trust; Royal Devon and Exeter NHS Foundation... and other collaboratorsCompletedLeukaemia (Acute) | Leukaemia (Chronic) | Leukaemia (Acute Myeloid) | Leukaemia (Acute Lymphoblastic) | Leukaemia (Acute Promyelocytic)United Kingdom
-
Sellas Life Sciences GroupCompletedAcute Myeloid Leukemia | Acute Lymphoblastic LeukemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyelodysplastic Syndrome (MDS)United States
-
Zhujiang HospitalSun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Shenzhen Geno-Immune...RecruitingMyelodysplastic Syndromes | Leukemia, Acute Myelogenous (AML) | Leukemia, Acute Lymphocytic (ALL)China
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)United States
-
University of ChicagoNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult Acute Myeloid Leukemia... and other conditionsUnited States
-
Sellas Life Sciences GroupMerck Sharp & Dohme LLC; Cancer Insight, LLCActive, not recruitingColorectal Cancer | Ovarian Cancer | Acute Myelogenous Leukemia | Small-cell Lung Cancer | Triple-negative Breast CancerUnited States
-
Sellas Life Sciences GroupUnknownMultiple Myeloma | Minimal Residual Disease | High-Risk CancerUnited States